Obstet Gynecol Sci.  2021 Sep;64(5):419-436. 10.5468/ogs.21123.

Role of microRNAs as biomarkers of cervical carcinogenesis: a systematic review

Affiliations
  • 1Department of Obstetrics & Gynaecology, International Medical Unversity, Seremban, Malaysia
  • 2International Medical University, Kuala Lampur, Malaysia
  • 3Department of Human Biology, Cell and Molecules, International Medical University, Kuala Lampur, Malaysia
  • 4Consultant Gynaecological Oncologist, Hospital Tuanku Jaffar, Seremban, Malaysia

Abstract

We performed a systematic review to identify the role of microRNAs (miRNAs) as biomarkers in the progression of cervical precancerous lesions. A comprehensive search of the Cochrane Controlled Register of Trials, PubMed, ScienceDirect, and Embase databases was performed for articles published between January 2010 and June 2020. The following Medical Subject Headings (MeSH) terms were searched: “microRNA” and “cervical” and “lesion.” All study designs that aimed to evaluate the correlation of miRNA expression with different precancerous cervical staging and/or cervical cancer were included, except for case reports and case series. Approximately 82 individual miRNAs were found to be significant in differentiating the stages of cervical carcinogenesis. Among the miRNAs, miR-21 is the most prevalent, and it is consistently upregulated progressively from normal cervical to worsening cervical lesion stages in both cell and serum samples. miR-205 has been shown to have a higher specificity than human papilloma virus testing in predicting the absence of high-grade squamous intraepithelial lesions (HSILs) in exfoliated cell samples. The tumor suppressor miRNAs miR-34, let-7, miR-203 miR-29, and miR-375 were significantly downregulated in low-grade squamous intraepithelial lesions, HSILs, and cervical cancer. We found significant dysregulated miRNAs in cervical carcinogenesis with their dynamic expression changes and ability to detect viral persistency, risk prediction of low-grade lesions (cervical intraepithelial neoplasia [CIN] 2) to high-grade lesions (CIN 3), and progression of CIN 3 to cancer. Their ability to discriminate HSILs from non-dysplastic lesions has potential implications in early diagnosis and reducing overtreatment of otherwise regressive early preinvasive lesions.

Keyword

miRNAs; Biomarkers; Uterine cervical neoplasms; Systematic review

Figure

  • Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart. HPV, human papillomavirus.


Reference

References

1. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017; 141:664–70.
Article
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424.
Article
3. Demarco M, Lorey TS, Fetterman B, Cheung LC, Guido RS, Wentzensen N, et al. Risks of CIN 2+, CIN 3+, and cancer by cytology and human papillomavirus status: the foundation of risk-based cervical screening guidelines. J Low Genit Tract Dis. 2017; 21:261–7.
Article
4. Lowy DR, Schiller JT. Papillomaviruses and cervical cancer: pathogenesis and vaccine development. J Natl Cancer Inst Monogr. 1998; (23):27–30.
Article
5. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007; 370:890–907.
Article
6. Frega A, Pavone M, Sesti F, Leone C, Bianchi P, Cozza G, et al. Sensitivity and specificity values of high-risk HPV DNA, p16/ki-67 and HPV mRNA in young women with atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL). Eur Rev Med Pharmacol Sci. 2019; 23:10672–7.
7. Persson M, Elfström KM, Brismar Wendel S, Weiderpass E, Andersson S. Triage of HR-HPV positive women with minor cytological abnormalities: a comparison of mRNA testing, HPV DNA testing, and repeat cytology using a 4-year follow-up of a population-based study. PLoS One. 2014; 9:e90023.
Article
8. Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, et al. A uniform system for microRNA annotation. RNA. 2003; 9:277–9.
Article
9. Siomi H, Siomi MC. Posttranscriptional regulation of microRNA biogenesis in animals. Mol Cell. 2010; 38:323–32.
Article
10. Farazi TA, Hoell JI, Morozov P, Tuschl T. MiRNAs and cancer. Adv Exp Med Biol Published Online First. 19. December. 2012; [Epub]. https://doi.org/10.1007/978-94-007-5590-1_1 .
Article
11. Visone R, Croce CM. MiRNAs and cancer. Am J Pathol. 2009; 174:1131–8.
Article
12. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007; 67:8699–707.
Article
13. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, Hammond SM. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev. 2006; 20:2202–7.
Article
14. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. OHRI. 2000. Jan. 1. [Epub]. http//www.ohri.ca/programs/clinical_epidemiology/oxford.asp .
15. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: systematic reviews of etiology and risk. JBI. 2020. May. 15. [Epub]. https://wiki.jbi.global/display/MANUAL/Chapter+7%3A+Systematic+reviews+of+etiology+and+risk .
Article
16. Babion I, Snoek BC, Novianti PW, Jaspers A, van Trommel N, Heideman DAM, et al. Triage of high-risk HPV-positive women in population-based screening by miRNA expression analysis in cervical scrapes; a feasibility study. Clin Epigenetics. 2018; 10:76.
Article
17. Babion I, De Strooper LMA, Luttmer R, Bleeker MCG, Meijer CJLM, Heideman DAM, et al. Complementarity between miRNA expression analysis and DNA methylation analysis in hrHPV-positive cervical scrapes for the detection of cervical disease. Epigenetics. 2019; 14:558–67.
Article
18. Wilting SM, van Boerdonk RA, Henken FE, Meijer CJ, Diosdado B, Meijer GA, et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer. 2010; 9:167.
Article
19. Wilting SM, Snijders PJ, Verlaat W, Jaspers A, van de Wiel MA, van Wieringen WN, et al. Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. Oncogene. 2013; 32:106–16.
Article
20. Ribeiro J, Marinho-Dias J, Monteiro P, Loureiro J, Baldaque I, Medeiros R, et al. miR-34a and miR-125b expression in HPV infection and cervical cancer development. Biomed Res Int. 2015; 2015:304584.
Article
21. Pereira PM, Marques JP, Soares AR, Carreto L, Santos MA. MicroRNA expression variability in human cervical tissues. PLoS One. 2010; 5:e11780.
Article
22. Malta M, Ribeiro J, Monteiro P, Loureiro J, Medeiros R, Sousa H. Let-7c is a candidate biomarker for cervical intraepithelial lesions: a pilot study. Mol Diagn Ther. 2015; 19:191–6.
Article
23. Sharma S, Hussain S, Soni K, Singhal P, Tripathi R, Ramachandran VG, et al. Novel MicroRNA signatures in HPV-mediated cervical carcinogenesis in Indian women. Tumour Biol. 2016; 37:4585–95.
Article
24. Shishodia G, Shukla S, Srivastava Y, Masaldan S, Mehta S, Bhambhani S, et al. Alterations in microRNAs miR-21 and let-7a correlate with aberrant STAT3 signaling and downstream effects during cervical carcinogenesis. Mol Cancer. 2015; 14:116.
Article
25. Jiménez-Wences H, Martínez-Carrillo DN, Peralta-Zaragoza O, Campos-Viguri GE, Hernández-Sotelo D, Jiménez-López MA, et al. Methylation and expression of miRNAs in precancerous lesions and cervical cancer with HPV16 infection. Oncol Rep. 2016; 35:2297–305.
26. Campos-Viguri GE, Jiménez-Wences H, Peralta-Zaragoza O, Torres-Altamirano G, Soto-Flores DG, Hernández-Sotelo D, et al. miR-23b as a potential tumor suppressor and its regulation by DNA methylation in cervical cancer. Infect Agent Cancer. 2015; 10:42.
Article
27. Bumrungthai S, Ekalaksananan T, Evans MF, Chopjitt P, Tangsiriwatthana T, Patarapadungkit N, et al. Up-regulation of miR-21 is associated with cervicitis and human papillomavirus infection in cervical tissues. PLoS One. 2015; 10:e0127109.
Article
28. Kawai S, Fujii T, Kukimoto I, Yamada H, Yamamoto N, Kuroda M, et al. Identification of miRNAs in cervical mucus as a novel diagnostic marker for cervical neoplasia. Sci Rep. 2018; 8:7070.
Article
29. Ivanov MK, Titov SE, Glushkov SA, Dzyubenko VV, Malek AV, Arkhangelskaya PA, et al. Detection of high-grade neoplasia in air-dried cervical PAP smears by a microRNA-based classifier. Oncol Rep. 2018; 39:1099–111.
Article
30. Lukic A, Di Properzio M, Carico E, De Vitis C, Giglio S, Bordi G, et al. MicroRNA-551b expression profile in low and high-grade cervical intraepithelial neoplasia. Eur Rev Med Pharmacol Sci. 2018; 22:4448–57.
31. Gocze K, Gombos K, Kovacs K, Juhasz K, Gocze P, Kiss I. MicroRNA expressions in HPV-induced cervical dysplasia and cancer. Anticancer Res. 2015; 35:523–30.
32. Sommerova L, Anton M, Bouchalova P, Jasickova H, Rak V, Jandakova E, et al. The role of miR-409-3p in regulation of HPV16/18-E6 mRNA in human cervical high-grade squamous intraepithelial lesions. Antiviral Res. 2019; 163:185–92.
Article
33. Xie H, Norman I, Hjerpe A, Vladic T, Larsson C, Lui WO, et al. Evaluation of microRNA-205 expression as a potential triage marker for patients with low-grade squamous intraepithelial lesions. Oncol Lett. 2017; 13:3586–98.
Article
34. Piersma SJ. Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Microenviron. 2011; 4:361–75.
Article
35. Okoye JO, Ngokere AA, Onyenekwe CC, Erinle CA. Comparable expression of miR-let-7b, miR-21, miR-182, miR-145, and p53 in serum and cervical cells: diagnostic implications for early detection of cervical lesions. Int J Health Sci (Qassim). 2019; 13:29–38.
36. Pfeffer SR, Yang CH, Pfeffer LM. the role of miR-21 in cancer. Drug Dev Res. 2015; 76:270–7.
Article
37. Zhang L, Liao Y, Tang L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res. 2019; 38:53.
Article
38. Lu J, Tan T, Zhu L, Dong H, Xian R. Hypomethylation causes MIR21 overexpression in tumors. Mol Ther Oncolytics. 2020; 18:47–57.
Article
39. Liu SS, Chan KKL, Chu DKH, Wei TN, Lau LSK, Ngu SF, et al. Oncogenic microRNA signature for early diagnosis of cervical intraepithelial neoplasia and cancer. Mol Oncol. 2018; 12:2009–22.
40. Ye J, Cheng XD, Cheng B, Cheng YF, Chen XJ, Lu WG. MiRNA detection in cervical exfoliated cells for missed high-grade lesions in women with LSIL/CIN1 diagnosis after colposcopy-guided biopsy. BMC Cancer. 2019; 19:112.
Article
41. Zhang J, Li S, Yan Q, Chen X, Yang Y, Liu X, et al. Interferon-β induced microRNA-129-5p down-regulates HPV-18 E6 and E7 viral gene expression by targeting SP1 in cervical cancer cells. PLoS One. 2013; 8:e81366.
Article
42. Wang J, Liu Y, Wang X, Li J, Wei J, Wang Y, et al. MiR-1266 promotes cell proliferation, migration and invasion in cervical cancer by targeting DAB2IP. Biochim Biophys Acta Mol Basis Dis. 2018; 1864:3623–30.
Article
43. Wang H, Zhang D, Chen Q, Hong Y. Plasma expression of miRNA-21, -214, -34a, and -200a in patients with persistent HPV infection and cervical lesions. BMC Cancer. 2019; 19:986.
Article
44. Zhou LL, Shen Y, Gong JM, Sun P, Sheng JH. MicroRNA-466 with tumor markers for cervical cancer screening. Oncotarget. 2017; 8:70821–7.
Article
45. Yang X, Yan Z, Yang H, Ni H, Zhang L, Wang Y. Clinical value of combined detection of miR-1202 and miR-195 in early diagnosis of cervical cancer. Oncol Lett. 2019; 17:3387–91.
Article
46. Wen F, Xu JZ, Wang XR. Increased expression of miR-15b is associated with clinicopathological features and poor prognosis in cervical carcinoma. Arch Gynecol Obstet. 2017; 295:743–9.
Article
47. Wang F, Shan S, Huo Y, Xie Z, Fang Y, Qi Z, et al. MiR-155-5p inhibits PDK1 and promotes autophagy via the mTOR pathway in cervical cancer. Int J Biochem Cell Biol. 2018; 99:91–9.
Article
48. Wang X, Wang HK, Li Y, Hafner M, Banerjee NS, Tang S, et al. microRNAs are biomarkers of oncogenic human papillomavirus infections. Proc Natl Acad Sci U S A. 2014; 111:4262–7.
Article
49. Wang Z, Wang W, Zhao W, Wang Z, Yang J, Wang W, et al. Folate inhibits miR-27a-3p expression during cervical carcinoma progression and oncogenic activity in human cervical cancer cells. Biomed Pharmacother. 2020; 122:109654.
Article
50. Wang L, Wang Q, Li HL, Han LY. Expression of MiR200a, miR93, metastasis-related gene RECK and MMP2/MMP9 in human cervical carcinoma--relationship with prognosis. Asian Pac J Cancer Prev. 2013; 14:2113–8.
51. Zeng K, Zheng W, Mo X, Liu F, Li M, Liu Z, et al. Dysregulated microRNAs involved in the progression of cervical neoplasm. Arch Gynecol Obstet. 2015; 292:905–13.
Article
52. Zhang J, Zheng F, Yu G, Yin Y, Lu Q. miR-196a targets netrin 4 and regulates cell proliferation and migration of cervical cancer cells. Biochem Biophys Res Commun. 2013; 440:582–8.
Article
53. Zhu Y, Han Y, Tian T, Su P, Jin G, Chen J, et al. MiR-21-5p, miR-34a, and human telomerase RNA component as surrogate markers for cervical cancer progression. Pathol Res Pract. 2018; 214:374–9.
Article
54. Sheedy FJ. Turning 21: Induction of miR-21 as a key switch in the inflammatory response. Front Immunol. 2015; 6:19.
Article
55. Li B, Hu Y, Ye F, Li Y, Lv W, Xie X. Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection. Int J Gynecol Cancer. 2010; 20:597–604.
Article
56. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18:997–1006.
Article
57. Dickson EL, Vogel RI, Geller MA, Downs LS Jr. Cervical cytology and multiple type HPV infection: a study of 8182 women ages 31–65. Gynecol Oncol. 2014; 133:405–8.
Article
58. El-Hefnawy T, Raja S, Kelly L, Bigbee WL, Kirkwood JM, Luketich JD, et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem. 2004; 50:564–73.
Article
59. Zummeren MV, Kremer WW, Leeman A, Bleeker MCG, Jenkins D, Sandt MV, et al. HPV E4 expression and DNA hypermethylation of CADM1, MAL, and miR124-2 genes in cervical cancer and precursor lesions. Mod Pathol. 2018; 31:1842–50.
Article
Full Text Links
  • OGS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr